PDCD1 and neoplasm: Indeed, the combination of guadecitabine with the anti-PD-1 pembrolizumab led to encouraging response rates, immunomodulation in the tumor tissue and/or in periphery, and evidence of demethylation in on-treatment lesions, with manageable toxicity18.